Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MiddleBrook, Deerfield Management Company L.P. deal

Healthcare investment fund Deerfield acquired MBRK's Keflex cephalexin business, excluding Keflex Pulsys, for $7.5 million up front. MBRK has an option to reacquire the assets

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE